AstraZeneca Sells Rights To Embattled Bipolar Drug For $35M
AstraZeneca has agreed to sell the rights to its antipsychotic Seroquel in the U.S. and Canada for $35 million, in a move that offloads the bipolar drug at the center of...To view the full article, register now.
Already a subscriber? Click here to view full article